Fibrolamellar carcinoma

Overview

Fibrolamellar carcinoma (FLC) is a rare, distinct variant of primary liver cancer (hepatocellular carcinoma) that predominantly affects adolescents and young adults with no underlying liver disease. Unlike conventional hepatocellular carcinoma (HCC), which typically arises in the setting of cirrhosis, chronic hepatitis B or C infection, or metabolic dysfunction-associated steatotic liver disease (MASLD), FLC occurs in a background of histologically normal liver parenchyma.

First described as a distinct clinicopathological entity by Craig and Peters in 1980, FLC accounts for approximately 1% to 5% of all primary liver malignancies. Despite its rarity, it represents a significant clinical challenge due to its propensity for late diagnosis, aggressive biological behavior, and historical resistance to conventional systemic therapies used for typical HCC.

The defining molecular hallmark of FLC is a somatic deletion on chromosome 19, resulting in a DNAJB1–PRKACA fusion transcript. This fusion creates a chimeric protein that drives constitutive Protein Kinase A (PKA) signaling, serving as both a diagnostic biomarker and a potential therapeutic target.

Epidemiology and Risk Factors

Key Epidemiological Points

• Age Distribution: While the median age is approximately 25 years, cases have been reported in children as young as 4 and adults up to 70.
• Etiology: The etiology remains unknown. There are no established environmental risk factors, lifestyle links (alcohol, smoking), or hereditary syndromes definitively linked to FLC. It is considered a de novo malignancy arising from a specific genetic accident in a hepatic progenitor cell or hepatocyte.
• Genetics: The DNAJB1–PRKACA fusion is a somatic event (acquired, not inherited). Germline mutations are not a feature; therefore, family screening is not indicated.

Pathogenesis and Molecular Biology

The discovery of the DNAJB1–PRKACA fusion gene (2014) revolutionized the understanding of FLC.

The Mechanism

1. Chromosomal Deletion: A ~400 kb deletion on the short arm of chromosome 19 (19p13.1).
2. Gene Fusion: This deletion fuses the 5′ end of the DNAJB1 gene (encoding a heat shock protein 40 co-chaperone) to the 3′ end of the PRKACA gene (encoding the catalytic subunit of Protein Kinase A, PKA).
3. Chimeric Protein: The resulting fusion protein retains the N-terminal dimerization/docking domain of DNAJB1 and the C-terminal kinase domain of PRKACA.
4. Constitutive Activation: Unlike wild-type PKA, which requires cyclic AMP (cAMP) for activation, the fusion protein is constitutively active and mislocalized within the cell. This drives uncontrolled phosphorylation of downstream targets (e.g., CREB, mTOR pathway), promoting proliferation, survival, and metabolic reprogramming.

Diagnostic Utility

• Immunohistochemistry (IHC): Antibodies against the junction region of the fusion protein (or loss of the DNAJB1 C-terminus) are highly sensitive and specific (>95%) for FLC.
• RT-PCR / RNA Sequencing: Detection of the fusion transcript remains the gold standard molecular confirmatory test.
• Exclusion: The fusion is absent in conventional HCC, hepatocellular adenoma, cholangiocarcinoma, and metastatic carcinomas to the liver.

Clinical Presentation: Symptoms

FLC is notoriously insidious in its early stages. Because it arises in a non-cirrhotic liver, patients lack the surveillance protocols (ultrasound/AFP monitoring) standard for chronic liver disease populations. Consequently, tumors are often large (median 10–15 cm) at the time of diagnosis.

Common Presenting Symptoms

1. Abdominal Mass or Distension (Most Common: 60–80%)

• Patients often notice a palpable, firm, non-tender mass in the right upper quadrant (RUQ) or epigastrium.
• Significant abdominal distension may occur due to sheer tumor bulk or malignant ascites (less common than in cirrhosis).

2. Abdominal Pain (40–60%)

• Visceral Pain: Dull, aching, poorly localized RUQ or epigastric discomfort caused by stretching of the liver capsule (Glisson’s capsule).
• Referred Pain: Right shoulder tip pain (phrenic nerve irritation via the diaphragm).
• Acute Pain: Sudden, severe pain may indicate tumor rupture with hemoperitoneum (a surgical emergency occurring in 5–10% of cases).

3. Constitutional / Systemic Symptoms (30–50%)

• Unexplained Weight Loss: Often significant (>10% body weight) over months.
• Fatigue and Malaise: Disproportionate to activity level.
• Low-Grade Fevers: “Neoplastic fevers” (Paraneoplastic syndrome).
• Night Sweats.

4. Gastrointestinal Symptoms

• Early Satiety: Due to gastric compression by a large left lobe or central tumor.
• Nausea/Vomiting: Mechanical obstruction or gastric compression.
• Obstructive Jaundice: Rare (<5%), occurs only with central tumors compressing the common hepatic duct or hilar lymphadenopathy.

5. Paraneoplastic Syndromes (Distinctive Features)

FLC has a higher association with specific paraneoplastic phenomena than conventional HCC:

• Hypophosphatemic Osteomalacia / “Tumor-Induced Osteomalacia” (TIO):
• Mechanism: Tumor overproduction of Fibroblast Growth Factor 23 (FGF23).
• Presentation: Bone pain, muscle weakness, fractures, low serum phosphate, high alkaline phosphatase, inappropriately low/normal 1,25-Vitamin D.
• Resolution: Typically resolves completely after curative resection.
• Gynecomastia: Reported in male patients (mechanism unclear, possibly hormonal dysregulation by tumor).
• Hypoglycemia: Rare (secretion of IGF-II or insulin-like factors).
• Erythrocytosis: Rare (EPO production).

6. Laboratory Findings at Presentation

How Does It Look: Radiology and Gross/Microscopic Pathology

This section details the visual characteristics of FLC across imaging modalities and pathology, crucial for diagnosis and staging.

1. Cross-Sectional Imaging (CT and MRI)

FLC typically presents as a large, solitary mass in a non-cirrhotic liver.

Computed Tomography (CT) – Triphasic Protocol (Arterial, Portal Venous, Delayed)

• Arterial Phase: Hypervascular enhancement (heterogeneous). The tumor enhances brightly due to abundant arterial supply.
• Portal Venous / Delayed Phase: “Washout” is atypical. Unlike conventional HCC, FLC often shows progressive, sustained, or delayed enhancement (persistent enhancement) due to the dense central fibrous stroma which retains contrast.
• Central Scar: Hallmark Feature (50–70% of cases). A stellate, low-attenuation central area representing dense fibrosis.
• Crucial Distinction: In FLC, the central scar is T1 hypointense / T2 hypointense on MRI (mature collagen) and enhances on delayed phases (fibrosis). In Focal Nodular Hyperplasia (FNH), the scar is T2 hyperintense (edema/vascular) and enhances early.
• Calcifications: Common (30–60%). Coarse, punctate, or stippled calcifications within the tumor or central scar. Rare in conventional HCC (<10%).
• Capsule: A fibrous pseudocapsule may be visible as a delayed enhancing rim.
• Vascular Invasion: Portal vein tumor thrombus (PVTT) occurs in ~15–25% at presentation; hepatic vein invasion less common.
• Lymphadenopathy: Regional (porta hepatis, periportal, celiac) nodal enlargement is frequent (~40–50%), often with central necrosis.

Magnetic Resonance Imaging (MRI) – Liver-Specific Contrast (Gadoxetate/Gadobenate)

• T1-weighted: Hypointense relative to background liver (due to low fat/glycogen content).
• T2-weighted: Markedly Hyperintense (“Light bulb” brightness). Higher signal than conventional HCC due to high water content in lamellar fibrosis and tumor cells.
• Diffusion Weighted Imaging (DWI): Restricted diffusion (high cellularity) in tumor septae; central scar shows facilitated diffusion (free water in fibrosis).
• Hepatobiliary Phase (HBP): Hypointense (Defect). FLC lacks functional hepatocytes (OATP transporters), so it does not take up hepatobiliary agents. This distinguishes it from FNH (iso/hyperintense) and hepatocellular adenoma (variable).

Ultrasound (US)

• Usually the initial screening tool.
• Appearance: Large, heterogeneous, predominantly hyperechoic or mixed echogenicity mass.
• Central scar appears as a hyperechoic linear/stellate focus with posterior acoustic shadowing (if calcified).
• Doppler: High vascularity in septae; avascular central scar.

2. Gross Pathology (Macroscopic Appearance)

• Size: Typically large (mean 10–15 cm; range 3–30+ cm).
• Shape: Well-circumscribed, often lobulated, solitary mass (multifocal in <10%).
• Capsule: Thick, fibrous pseudocapsule (often incomplete).
• Cut Surface:
• Color: Pale white, tan, or yellowish-white (distinct from the dark green/brown of conventional HCC in cirrhotic liver). The pallor is due to low bile content, low lipid, and dense fibrosis.
• Texture: Firm, gritty, or rubbery (scirrhous) due to abundant collagen.
• Central Scar: Prominent, stellate, firm, white fibrous core radiating outward.
• Calcifications: Gritty, white flecks palpable on sectioning.
• Necrosis/Hemorrhage: Less common than in conventional HCC; usually peripheral if present.

3. Microscopic Pathology (Histology)

The name “Fibrolamellar” derives from the microscopic architecture: Fibro- (fibrosis) and Lamellar (layered/plates).

Defining Histological Triad

1. Large Polygonal Tumor Cells:

• Abundant, granular, eosinophilic (pink) cytoplasm (mitochondria-rich).
• Large, vesicular nuclei with prominent nucleoli (often macronucleoli).
• Low nuclear-to-cytoplasmic ratio.

1. Lamellar Fibrosis (Collagen Bands):

• Thick, parallel bands of dense collagen (lamellae) separating tumor cells into nests, trabeculae, or pseudo-glands.
• “Parallel lamellae” resemble the layers of a croissant or plywood.

1. Pale Bodies (Intracytoplasmic Inclusions):

• Membrane-bound, PAS-positive, diastase-resistant, eosinophilic globules in the cytoplasm.
• Represent dilated endoplasmic reticulum / autophagic vacuoles.
• Highly characteristic (seen in >80%), but not 100% specific.

Other Histologic Features

• Bile Production: Rare, usually focal, canalicular pattern (explains low AFP/normal LFTs).
• Mitotic Activity: Variable; generally low to moderate. Atypical mitoses may be seen.
• Invasion: Perineural invasion common; vascular invasion less frequent than conventional HCC at similar sizes.
• Background Liver: Histologically normal. No cirrhosis, no significant steatosis, no chronic hepatitis.

Immunohistochemistry (IHC) Profile

Staging and Prognostic Factors

Because FLC is rare, it is typically staged using the AJCC 8th Edition TNM Staging for HCC, though this system is optimized for cirrhosis. The Barcelona Clinic Liver Cancer (BCLC) staging is not validated for FLC (relies on liver function/Child-Pugh).

AJCC 8th Edition TNM (Simplified for FLC Context)

Prognostic Factors Specific to FLC

1. Resection Margin Status (R0 vs R1/R2): Single most important factor. Achieving a microscopically negative margin (R0) is the primary determinant of long-term survival.
2. Lymph Node Status (N1): Presence of regional nodal metastasis significantly worsens prognosis, but long-term survivors exist with aggressive lymphadenectomy + systemic therapy.
3. Vascular Invasion: Microvascular invasion (MVI) on final pathology portends higher recurrence risk.
4. Tumor Size: >10–12 cm associated with worse outcomes (surrogate for resectability/biology).
5. Response to Neoadjuvant Therapy: Pathologic response (necrosis) may predict better outcome.
6. FGF23 / Osteomalacia: Presence of paraneoplastic syndrome does not independently worsen cancer-specific survival if resected.

Management and Treatment Strategies

Treatment requires a Multidisciplinary Team (MDT) approach (Hepatobiliary Surgery, Medical Oncology, Radiology, Pathology, Interventional Radiology, Radiation Oncology, Genetics).

1. Surgical Resection: The Curative Standard

• Indication: Technically resectable disease with sufficient Future Liver Remnant (FLR >20–30% in healthy liver). No underlying cirrhosis makes major hepatectomy safer than in conventional HCC.
• Extent: Anatomic resection preferred (hemihepatectomy, trisegmentectomy) to ensure margins. Parenchymal-sparing non-anatomic resection acceptable for peripheral small tumors if R0 achievable.
• Lymphadenectomy: Routine regional lymphadenectomy (porta hepatis, celiac axis) is recommended at time of resection for staging and potential therapeutic benefit (N1 disease upstages to IVA but resection may still offer survival benefit).
• Rupee: R0 resection is the goal. Positive margins (R1) carry near 100% recurrence risk.
• Minimally Invasive: Laparoscopic/Robotic major hepatectomy feasible in high-volume centers for selected tumors.

2. Liver Transplantation (LT)

• Controversial / Evolving Role.
• Traditional View: High recurrence rates (30–50%+) post-transplant due to aggressive biology and micrometastases; extrahepatic disease (nodes/lung) often missed.
• Current Selection Criteria (Consensus Emerging):
• Unresectable but liver-confined disease (no extrahepatic mets).
• Mandatory: No nodal metastasis (N0) on high-quality imaging/PET.
• Neoadjuvant “Bridge” Therapy: Often required (see below) to demonstrate tumor biology control.
• Milan Criteria not validated; “Downstaging” protocols used.
• Outcomes: 5-year OS ~50–65% in highly selected modern series (better than historical 20–30%). Recurrence remains the main cause of death.

3. Systemic Therapy (Advanced/Metastatic/Neoadjuvant/Adjuvant)

Conventional HCC regimens (Sorafenib, Lenvatinib, Atezolizumab/Bevacizumab) have POOR activity in FLC. FLC is immunologically “cold” (low TMB, low PD-L1, low infiltration) and lacks VEGF dependence.

Active Regimens (Evidence-Based)

Adjuvant Therapy

• No Standard. No randomized trials.
• Practice: Often 4–6 months of GemCis considered for high-risk features (R1 margin, N1 nodes, MVI, large size >10cm). Decision individualized via MDT.

Neoadjuvant Therapy

• Goal: Downstage unresectable → resectable; treat micrometastases; assess biology (responders do better).
• Regimen: GemCis x 4–6 cycles.
• Assessment: RECIST 1.1 + CA19-9/AFP trends + PET-CT. Surgery typically 4–6 weeks post-last cycle.

4. Locoregional Therapies (LRT)

• Role: Primarily bridging/downstaging for transplant candidates or palliation for oligometastatic disease. Not curative for primary tumor due to size/fibrosis (poor heat conduction for ablation, poor drug penetration for TACE).
• TACE (Transarterial Chemoembolization): Limited efficacy (hypovascular stroma, lack of cirrhosis alters arterial anatomy). Drug-eluting beads (DEB-TACE) slightly better.
• TARE (Y-90 Radioembolization): Better tolerated; used for downstaging/bridge to transplant.
• Ablation (RFA/MWA): Only for very small (<3cm) peripheral lesions; heat-sink effect from large vessels/stroma limits efficacy.
• SBRT (Stereotactic Body Radiation Therapy): Excellent local control for unresectable primary, nodal mets, or lung oligomets. Increasingly used in multimodal paradigms.

5. Management of Paraneoplastic Syndromes

• TIO (Hypophosphatemia/Osteomalacia): Oral Phosphate + Active Vitamin D (Calcitriol) supplementation. Definitive cure = Tumor Resection. Monitor renal function (nephrocalcinosis risk).
• Gynecomastia: Usually resolves post-resection; Tamoxifen trial if persistent/painful.

Follow-Up and Surveillance

Due to high recurrence rates (50–70% even after R0 resection) and late recurrences (>5 years), lifelong surveillance is mandatory.

Recommended Surveillance Protocol (Consensus-Based)

PET-CT (FDG): FLC is FDG-avid (unlike well-differentiated HCC). Useful for staging, restaging, and detecting extrahepatic recurrence (nodes, lung, bone, peritoneum) where CT/MRI equivocal. Consider annually or for problem-solving.

Special Populations

Pediatric and Adolescent Patients

• Biology identical to young adults.
• Fertility Preservation: Critical discussion before chemotherapy (GemCis) or pelvic radiation. Sperm banking / Oocyte cryopreservation.
• Growth/Development: Long-term monitoring for anthracycline cardiotoxicity (if used in trials), cisplatin ototoxicity/nephrotoxicity, secondary malignancies.
• Psychosocial: AYA (Adolescent Young Adult) oncology support programs essential.

Pregnancy

• Extremely rare scenario.
• Diagnosis: MRI without contrast (avoid Gadolinium); US.
• Management: MDT decision balancing maternal vs fetal risk.
• 1st Trimester: Delay surgery/chemo if possible (teratogenicity). Termination discussed.
• 2nd/3rd Trimester: Resection feasible (2nd trimester safest). GemCis contraindicated (Category D). Delay systemic therapy until postpartum if possible.
• Delivery: Plan for C-section if large tumor risks rupture during labor.

Current Research and Future Directions

1. Targeting the PKA Fusion:

• Direct Inhibitors: Developing small molecules targeting the unique junction of DNAJB1-PRKACA.
• PKA Inhibitors: Targeting the hyperactive kinase domain.
• Disrupting Scaffolding: Targeting the DNAJB1 dimerization domain.

1. MAPK/ERK Pathway Inhibition:

• MEK Inhibitors (Trametinib, Binimetinib, Selumetinib): Strong preclinical rationale; PKA activates RAF/MEK/ERK. Early clinical signals of activity. Clinical trials ongoing.

1. Immunotherapy Sensitization:

• FLC is “Cold.” Strategies: Epigenetic modulators (HDACi, DNMTi) to upregulate MHC/neoantigens; STING agonists; Oncolytic viruses; Combination with Chemo (GemCis + IO).

1. FGF23 Targeting:

• Burosumab (Anti-FGF23 Antibody): Approved for XLH; used off-label for severe FLC-TIO to normalize phosphate pre-operatively.

1. Liquid Biopsy / ctDNA:

• Detecting DNAJB1-PRKACA fusion in circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) monitoring post-resection and early recurrence detection.

1. Patient-Derived Models:

• Organoids, PDX models, cell lines (rare) to test drug screens.

Patient Support and Resources

A diagnosis of a rare cancer in young adulthood is uniquely isolating. Connection to specialized centers and advocacy groups improves access to trials and psychosocial support.

• Fibrolamellar Cancer Foundation (FCF): Primary advocacy/research funding organization. Patient registry, travel grants, scientific meetings.
• Children’s Oncology Group (COG) / Pediatric Liver Tumor Consortium: For patients <18-21 years.
• NCI Rare Tumors Initiative / MyPART Network: Natural history studies, telehealth consults.
• ClinicalTrials.gov: Search “Fibrolamellar” + “DNAJB1-PRKACA”.
• Genetic Counseling: Recommended to discuss somatic vs germline testing implications (though FLC is somatic, young cancer diagnosis warrants germline panel per NCCN guidelines).

Summary of Key Takeaways for Patients and Providers

1. FLC is NOT typical Liver Cancer. It hits young, healthy people. Normal liver background = Surgery is usually well tolerated.
2. AFP is NOT a reliable marker. Normal AFP does not rule it out. Diagnosis requires Imaging + Biopsy (IHC for DNAJB1-PRKACA fusion).
3. Surgery (R0 Resection) is the only potential cure. Seek a High-Volume Hepatobiliary Surgeon at a major center.
4. Standard HCC Chemo (Sorafenib, Immunotherapy alone) DOES NOT WORK well. Ask about Gemcitabine/Cisplatin and Clinical Trials (MEK inhibitors, Novel combos).
5. Lymph Nodes: If involved, it’s Stage IVA, but aggressive resection + systemic therapy can still yield long-term survival.
6. Watch your Bones/Phosphate. Bone pain? Check Phosphate, ALP, FGF23. It’s treatable and reversible.
7. Surveillance is for LIFE. Recurrences happen late. Annual MRI/Chest CT indefinitely.
8. You are not alone. Connect with the Fibrolamellar Cancer Foundation and seek care at a Center of Excellence.

References

1. Craig, J.R. and Peters, R.L. (1980) ‘Fibrolamellar carcinoma: a distinct clinicopathologic entity’, Cancer, 46(2), pp. 361–367.
2. Honeyman, J.N. et al. (2014) ‘Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma’, Science, 343(6174), pp. 1010–1014.
3. Simon, S.M. et al. (2018) ‘Fibrolamellar hepatocellular carcinoma: a molecular perspective’, Journal of Hepatology, 68(5), pp. 1022–1031.
4. Krane, J.F. et al. (2017) ‘Fibrolamellar hepatocellular carcinoma: a comprehensive review’, Archives of Pathology & Laboratory Medicine, 141(10), pp. 1325–1334.
5. Swisshelm, K. et al. (2021) ‘Immunohistochemical detection of the DNAJB1-PRKACA fusion protein in fibrolamellar hepatocellular carcinoma’, Modern Pathology, 34(1), pp. 178–186.
6. Lu, S. et al. (2020) ‘Clinical outcomes and prognostic factors in fibrolamellar hepatocellular carcinoma: a multi-institutional analysis’, Journal of the American College of Surgeons, 230(4), pp. 589–600.e2.
7. Al-Saab, S. et al. (2019) ‘Systemic therapy for advanced fibrolamellar hepatocellular carcinoma: a systematic review’, Journal of Gastrointestinal Oncology, 10(5), pp. 987–996.
8. Sanoff, H.K. et al. (2022) ‘MEK inhibition in fibrolamellar carcinoma: a case series and review of the literature’, The Oncologist, 27(4), pp. e298–e304.
9. Amin, M.B. et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer International Publishing.
10. European Association for the Study of the Liver (EASL) (2023) ‘Clinical Practice Guidelines on management of hepatocellular carcinoma (including FLC section)’, Journal of Hepatology, 78(1), pp. 1–52.
11. NCCN Guidelines (2024) Hepatobiliary Cancers, Version 2.2024. National Comprehensive Cancer Network. Available at: https://www.nccn.org (Accessed: [Current Date]).
12. Zhang, X. et al. (2023) ‘Circulating tumor DNA detection of DNAJB1-PRKACA fusion for monitoring minimal residual disease in fibrolamellar carcinoma’, Clinical Cancer Research, 29(12), pp. 2145–2154.
13. O’Reilly, E.M. et al. (2021) ‘Fibrolamellar hepatocellular carcinoma: current management and future directions’, American Society of Clinical Oncology Educational Book, 41, pp. 1–12.
14. Argani, P. et al. (2020) ‘The morphologic spectrum of fibrolamellar carcinoma: a multi-institutional study of 100 cases’, American Journal of Surgical Pathology, 44(8), pp. 1031–1042.
15. Fibrolamellar Cancer Foundation (2024) Patient Handbook: Understanding Fibrolamellar Carcinoma. 3rd edn. Greenwich, CT: FCF Publications.